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DOI 10.1002/ajmg.b.32344Recent studies have revealed the polygenic nature of bipolar
disorder (BP), and identified common risk variants associated
with illness. However, the role of common polygenic risk in
multiplex families has not previously been examined. The
present study examined 249 European-ancestry families from
the NIMH Genetics Initiative sample, comparing subjects with
narrowly defined BP (excluding bipolar II and recurrent unipo-
lar depression; n¼ 601) and their adult relatives without BP
(n¼ 695). Unrelated adult controls (n¼ 266) were from the
NIMH TGEN control dataset. We also examined a prospective
cohort of young (12–30 years) offspring and siblings of individ-
uals with BPI and BPII disorder (at risk; n¼ 367) and psychiat-
rically screened controls (n¼ 229), ascertained from five sites in
the US and Australia and assessed with standardized clinical
protocols. Thirty-two disease-associated SNPs from the PGC-BP
Working Group report (2011) were genotyped and additive
polygenic risk scores (PRS) derived. We show increased PRS
in adult cases compared to unrelated controls (P¼ 3.4 105,
AUC¼ 0.60). In families with a high-polygenic load (PRS score
32 in two or more subjects), PRS distinguished cases with BPI/
SAB from other relatives (P¼ 0.014, RR¼ 1.32). Secondly, a
higher PRS was observed in at-risk youth, regardless of affected
status, compared to unrelated controls (GEE-x2¼ 5.15,015 The Authors. American Journal of Medical Genetics Part B: NeuP¼ 0.012). This report is the first to explore common polygenic
risk in multiplex families, albeit using only a small number ofropsychiatric Genetics Published by Wiley Periodicals, Inc. 617
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the potential utility of PRS assessment in a family context.
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INTRODUCTION
Large scale collaborative genome-wide association studies (GWAS)
have identified a number of risk loci significantly associated with
bipolar disorder (BP), includingODZ4 [Sklar et al., 2011;Muhleisen
et al., 2014], CACNA1C [Ferreira et al., 2008; Sklar et al., 2008],
ANK3 [Ferreira et al., 2008; Schulze et al., 2009; Muhleisen et al.,
2014],NCAN [Cichonet al., 2011],C15ORF53 [Ferreira et al., 2008],
and DGKH [Baum et al., 2008a,b]. Individually, each of those
genes/loci contributes only a small fraction toward overall disease
risk, typically<1%of the phenotypic variance [Ferreira et al., 2008].
It is now understood that multiple genes containing both common
and rare variants contribute to the genetic architecture of BP
[Sullivan et al., 2012], and there are significant overlaps in the single
nucleotide polymorphism (SNP)-based heritabilities of BP with
both schizophrenia andmajor depression [Lee et al., 2013]. Indeed,
variation across many thousands of common risk variants together
(termed polygenic risk [Purcell et al., 2009]) contributes a substan-
tial proportion (i.e., 25–40%) of the percentage of phenotypic
variance at a population level [Lee et al., 2011; 2013]—although
most of those loci do not individually reach genome-wide signifi-
cance thresholds for disease association with current sample sizes
[Craddock and Sklar, 2013; Dudbridge, 2013].
Examination of the cumulative effects of inheriting multiple risk
alleles—each of which are significantly or nominally associatedwith
disease risk—has been able to powerfully differentiate groups of
cases from controls in independent population-based studies
[Purcell et al., 2009, 2014; Patel et al., 2010; Ayalew et al., 2012;
TerwisschavanScheltingaet al., 2012].However, despitephenotypic
aggregation within families [McGuffin et al., 2003; Lichtenstein
et al., 2009], no studies have so far examined polygenic risk incor-
porating these common genetic factors in a family context in adults,
withonlyonegroup todate reportingonpolygenic risk inadolescent
offspring of individuals with BP [Whalley et al., 2012, 2013].
While first-degree relatives of individuals affected with BPwould
be expected on a theoretical basis to have a higher load of specific
disease-associated risk alleles than control individuals, this has not
previously been examined empirically. This is primarily because,
until recently, we have had very little knowledge about the specific
DNAvariants that contribute to risk forBP.However, as sample sizes
are steadily increasing through the Psychiatric Genomics Consor-
tium (PGC), and our power to detect such risk variants on a
population level is improving, we are gaining a greater understand-
ing of the underlying genetic contributors leading to BP. In 2011,
Sklar et al. identified 38 variants (pared to 34 by assessment ofindependence with linkage disequilibrium) that contribute to dis-
ease risk (P< 5 105) using a discovery sample of 7,481 individu-
als with BP and 9,250 controls. These SNPs were replicated in an
independent cohort comprising 4,496 cases and 42,422 controls,
with more SNPs than expected showing P< 0.01, P< 0.05, and the
same direction of effect [Sklar et al., 2011]. Hence, a substantial
numberof theseSNPsmaybeexpected to represent true riskvariants
(ormarkers for such alleles) for bipolar disorder.Here,we examined
polygenic risk derived from those specific variants in first degree
relatives of individuals with BP.
The present study tested the hypothesis that first-degree relatives
who are affected with BPwould have a higher polygenic risk load of
common risk variants in comparison to their relatives without BP,
and that individuals at increased familial risk of BP would have a
higher polygenic load of risk variants than control individuals. We
tested this hypothesis using three cohorts: (1) a group of singleton
cases with BP and controls from the National Institute of Mental
Health (NIMH); (2) a family cohort of adult relatives of individuals
with andwithout diagnoses of BP from theNIMHBipolar Genetics
Initiative; and (3) a prospective cohort of adolescents and young
adults who are at increased familial risk of developing BP due to the
presence of a first degree relative with a diagnosis of BP (henceforth
termed “at-risk”) and controls.MATERIALS AND METHODS
Adult Participants From Family Studies
Two datasets were employed. The first comprised adult subjects
of European ancestry (n¼ 1,947) drawn from the NIMH Genet-
ics Initiative bipolar disorder family samples (waves I–IV Euro-
pean American families, n¼ 249 families, average of 6–7 subjects
across three generations per family) [Nurnberger et al., 1997;
Smith et al., 2009]. Subject diagnoses were obtained via standard
best estimate (BEFD) procedure (details in supplementary infor-
mation), and were diagnosed as having bipolar disorder type I
(BPI, n¼ 561); schizoaffective disorder-bipolar type (SAB,
n¼ 40); bipolar disorder type II (BPII, n¼ 119); recurrent uni-
polar depressive disorder (UPR, n¼ 155); or single episode
unipolar depressive disorder (UPS, n¼ 107). Primary analysis
utilized a narrow definition of case status, whereby subjects were
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(n¼ 601). Subjects with BPII and UPR (n¼ 274) were excluded
on the basis of unknown overlapping etiology, as were relatives
with unknown diagnosis (n¼ 85). All other relatives (n¼ 695)
included those with other mental disorders ([i.e., those with any
DSM diagnosis excluding BPI, SAB, BPII, or UPR, n¼ 292],
never mentally ill [n¼ 296], or with single episode depression
[n¼ 107]), and were analyzed as a single group. Due to the small
numbers of relatives with no psychiatric diagnoses (i.e., only one
per family) comparisons between cases and never mentally ill
relatives were not attempted.
The comparison dataset comprised unrelated adult controls of
European origin drawn from the NIMH TGEN Control dataset
subjects (n¼ 403) from the control collection of Sanders et al.
[2010], who were screened to exclude those with any major mood
disorder or psychosis (https://www.tgen.org/). DNA was extracted
from whole blood by the Rutgers University Cell and DNA
Repository.Young At-Risk Participants
Subjects were aged between 12 and 30 years, and were ascertained
from five independent sites in the US [Nurnberger et al.,
2011] (Johns Hopkins University; University of Michigan; Wash-
ington University in St. Louis; Indiana University) and Australia
[Roberts et al., 2013] (University of New South Wales). “At-risk”
subjects were recruited from families who had previously partici-
pated in BP genetics studies [Nurnberger et al., 1997; Dick et al.,
2003; Fullerton et al., 2010], a specialized BP research clinic
[Mitchell et al., 2009], were referred by clinicians or mental health
consumer organizations, or responded to other forms of publicity.
Subjects were recruited using a “top-down” ascertainmentmethod:
that is, all offspring of a proband with a confirmed DSM-IV
diagnosis of bipolar disorder type I (BPI), type II (BPII), or
schizoaffective disorder bipolar-type (SAB) who were in the age
range 12–30 were eligible for inclusion, independent of the diag-
nostic status of the offspring. The participants were predominantly
(94%) children or siblings of a proband; the remaining 6%
comprised second-degree relatives ascertained from families
with multiple cases of BP. Control participants were in the same
age range, but had no first-degree relative (parent or sibling) with a
DSM-IV diagnosis of BPI or BPII, SAB, recurrentmajor depression
(UPR), schizophrenia, recurrent substance abuse, or any past
psychiatric hospitalization; and no parent with a first-degree
relative who had a past mood disorder hospitalization or history
of psychosis. Control subjects were recruited via general medical
clinics, motor vehicle records, print and electronic media, and
notice boards in universities and local communities.
Peripheral blood samples were collected from a total of 367 at-
risk and 229 control individuals for genetic analysis. DNA was
extracted from whole blood by the Rutgers University Cell and
DNA Repository (US participants) or Genetic Repositories
Australia (Australian participants). The 596 participants came
from 426 families: the majority being single offspring (n¼ 299);
although 127 families with 2 offspring were included (90 with 2
offspring, 30 with 3 offspring, 5 with 4 offspring, and 2 with 5
offspring).Institutional Review Board Approval
Written informed consent (or assent with parental consent for
subjects <18 years old) was obtained from all participants after a
thorough explanation of the study. All protocols were approved
through the individual hospital and University ethics committees
(Institutional Review Boards) at each of the participating US
university medical centers, University of New South Wales Human
Research EthicsCommittee, and the South Eastern Sydney Illawarra
Area Health Service, Australia.Ascertainment of Clinical Diagnoses and
Demographic Information
Methods for ascertainment and diagnoses for the NIMH Genetics
Initiative family dataset have been described extensively elsewhere
[Nurnberger et al., 1997; Smith et al., 2009] and are summarized in
supplementary information.
For the at-risk cohort, proband consensus DSM-IV diagnoses
were determined by two independent psychiatrists using best esti-
mate methodology [Leckman et al., 1982], using information from
an adapted version of the Schedule for Affective Disorders and
Schizophrenia for School-Age Children—Present and Lifetime
Version (K-SADS-BP) [Kaufman et al., 1997; Geller et al., 2001],
the Diagnostic Interview for Genetic Studies (DIGS) Version 4
[Nurnberger et al., 1994], the Family Interview for Genetic Studies
(FIGS) [Maxwell, 1992], andmedical records (where available). For
participants under the age of 22, the K-SADS-BP was administered
as the diagnostic instrument. The FIGS was administered to all
participants 18 years of age or older, with parents completing FIGS
for participants under 18. Ethnicity was assessed by self-report via
grandparental origin information. The at-risk cohort was mainly of
European ancestry (73%), with subjects of Asian and African
ancestry each accounting for less than 10% of the sample (Table I).Marker Selection, Genotyping, and Quality
Control
We chose for genotyping 38 SNPs that were robustly implicated in
bipolar disorder risk, on the basis of prior evidence of genetic
association (P< 5 105) from the PGC [Sklar et al., 2011]; two
(rs3968, rs8006348) failed sassay design.
The remaining 36 SNPs [Sklar et al., 2011] were genotyped at
two sites, using iPLEX GOLD chemistry on the Sequenom Mas-
sArray (Supporting Information Table S1]. Tests for Hardy–Wein-
berg equilibrium, linkage disequilibrium, genotype missingness
and allelic, and genotypic frequency comparisons were conducted
using PLINK [Purcell et al., 2007]. Three failed genotyping or
Hardy–Weinberg equilibrium (P< 0.001) in either the US or
Australian at-risk sample (rs12912251, rs4332037, rs7578035),
and one was in linkage disequilibrium with another SNP
(rs11168751 with rs2070615; r2¼ 0.141, D0 ¼ 1.0). These SNPs
were excluded from polygenic risk score analysis, leaving 32
SNPs for determination of polygenic risk score. The successfully
genotyped SNPs had a >99.6% genotype pass rate.
NIMH controls were genotyped on the Affymetrix 6.0 array.
Imputation was employed via IMPUTE v0.5.0 [Marchini et al.,
TABLE I. Racial Background of Combined United States and Australian At-Risk and Control Samples
All subjects (%) At-risk (%) Control (%)
European 478 (78.5) 335 (91.3) 143 (62.4)
Asian 38 (6.2) 1 (0.3) 37 (16.2)
African 40 (6.6) 5 (1.4) 35 (15.3)
Mixed race/other/unknown 53 (8.7) 26 (7.0) 14 (6.1)
Total 609 (100) 367 (100) 229 (100)
The total number of individuals in each racial group (reported in line with the seven US census categories) is given, along with the percentage (%) representation within each sample. The numbers of
individuals represented in the mixed race/other/unknown category were of Australian Aboriginal/Hawaiian/Pacific Islander (n¼ 7), American Indian/Alaska native (n¼ 1), mixed race (n¼ 18), or other/
unknown (n¼ 27) descent.
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the array, using genotypes from Caucasian European individuals
(n¼ 82) fromHAPMAP3 release 24 as a reference panel. Themean
concordance of imputed and observed genotype calls was 97.4%.
The majority of SNPs (n¼ 26) imputed with <10% missing data,
but some SNPs had higher failure rates (Supporting Information
Table S1). The allele frequencies of each SNP in all European
ancestry subjects were close to those previously reported [Sklar
et al., 2011] for Europeans (0.022–0.032), and were similar for
both directly observed and imputed SNPs (0.031 and 0.025,
respectively) (Supporting Information Table S1).Polygenic Risk Score Determination
To determine the additive polygenic load in each subject, a score of
one was given for each risk allele carried, so an individual subject’s
score could range from 0 to 64. Weighted-additive polygenic risk
scores were computed using the score function in PLINK [Purcell
et al., 2007]. Scores were weighted either by: (1) the effect size of
each SNP, as determined by the odds ratio of the risk allele from the
original discovery GWAS study by Sklar et al. [2011]; or (2) by
the PGC risk allele frequency from appropriate ethnic group to
derive ethnicity-specific PRS, using allele frequencies determined
the phase 1 of the 1000 genomes project [Abecasis et al., 2012].
Frequencies derived fromCEPH individuals (CEU)were applied to
people of European ancestry, frequencies from individuals of
African ancestry from south west US (ASW) were applied to
African-American individuals, and frequencies from Han Chinese
individuals from Beijing (CHB) were applied to individuals of
Asian ancestry.
For the at-risk and NIMH family samples, only individuals with
no missing genotypes (n¼ 364 at-risk, n¼ 226 young controls,
n¼ 601 NIMHBPI/SAB cases [including 236 singletons]), n¼ 969
other NIMH relatives (including subjects with diagnoses of BPII
and UPR) were included. As imputation was required for deter-
mination of genotypes in unrelated controls, a maximum of two
missing genotypes were permitted (n¼ 266 NIMH TGEN con-
trols), and the score normalized to a base of 64. For the comparison
of polygenic risk scores between singleton bipolar cases from the
NIMHbipolar genetics initiative and TGEN controls, subjects were
only included if a minimum of 31 SNPs were successfully geno-
typed (directly or by imputation), and polygenic risk scores were
adjusted on the basis of the total number of variants used.Statistical Analysis
To test whether cases or at-risk individuals within families had a
higher averagepolygenic risk score as comparedwith controls, a linear
GeneralizedEstimatingEquations (GEE)modelwasused,with aone-
sided test for significance. The GEEmodel corrects for non-indepen-
dence of measurement between family members. A one-sided t-test
was utilized to test group differences in unrelated subjects. Relative
risk calculations were conducted relative to the mean polygenic risk
value for the case (bipolar disorder or at-risk) group. Statistical
analysis was conducted in SPSS (Version 20.0, IBM Corporation,
Armonk, NY). Estimates of the proportion of genetic variance
accounted for by the score were calculated via genRoc (http://glim-
mer.rstudio.com/kn3in/genRoc/) [Wray et al., 2010] and GPRS
software (https://gprs.shinyapps.io/start/) [Dudbridge, 2013].RESULTS
Using polygenic risk scores derived from 32 of the most robustly
associated SNPs from the PGC, we conducted a risk load analysis to
determine whether a polygenic risk score derived from disease-
associated SNPs would: (1) distinguish unrelated BP cases from
unrelated control individuals; (2) distinguish relatives affectedwith
BP from their non-BP-affected or “unaffected” adult relatives; and
(3) distinguish a young at-risk population from a group of unre-
lated young controls.Polygenic Risk Load Analysis in Adult Cases
Versus Unrelated Adult Controls
We used European ancestry subjects from 249 bipolar pedigrees
from theNIMHgenetics initiative sample.We selected a single case
with BPI or SAB from each of the families (n¼ 236; typically the
first subject recruited with a diagnosis of BPI or SAB for each family
for whom the maximum number of SNPs were successfully gen-
otyped) and compared polygenic risk scores to unrelated controls
from the NIMH control dataset (n¼ 266).
We found that the average polygenic risk score was higher for
singleton BPI or SAB cases than unrelated controls [mean¼ 32.67
 3.85 and 31.35 3.90, respectively; t(1,501)¼3.81, P¼ 7.08
E-05, OR¼ 1.88 (95%CI¼ 1.31–2.69)] and that a score of32 risk
alleles (defined by mean of the case group) was associated with an
increased relative risk of BP diagnosis of 1.31 (95%CI¼ 1.12–1.53)
FIG. 1. Risk allele score distribution comparing unrelated
controls and singleton cases from NIMH families. Single cases
with BPI or SAB (n¼ 236, grey bars) were selected from NIMH
families and compared to unrelated controls from the TGEN
dataset (n¼ 266, white bars). The relative risk (RR) estimate of
1.31 (95%CI¼ 1.12–1.53) was calculated with respect to a risk
score of 32, with an overall odds ratio of 1.88 (95%CI¼ 1.31–
2.69). For the purposes of graphical representation, the frequen-
cy of risk scores are represented in even integers, and represent
bins which include both odd and even scores (i.e., bin 22 is the
sum of the frequency of 22 and 23 risk alleles).
TABLE II. Summary of Area Under the Receiver-Operator
Characteristic Curve (AUC), With Incremental Increase of SNP
Content in Polygenic Risk Score
Number of SNPs AUC (95%CI) P-value
10 0.528 (0.477–0.578) 0.287
13 0.548 (0.498–0.599) 0.062
14 0.554 (0.504–0.605) 0.037
15 0.556 (0.506–0.607) 0.029
20 0.573 (0.523–0.624) 0.0045
25 0.597 (0.547–0.646) 1.85E-04
30 0.606 (0.557–0.655) 4.24E-05
32 0.601 (0.552–0.651) 9.13E-05
SNPs were included in the polygenic risk score in order of decreasing odds ratio from the primary
GWAS reported by Sklar et al. (2011); and polygenic risk scores weighted by the odds ratio for
each SNP. Mean AUC estimates are given, along with the 95% confidence interval of each
measure.
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frequency (P¼ 0.0025) and odds ratio (P¼ 3.55E-05).Sensitivity and Specificity of the SNP Panel
To determine the sensitivity and specificity of this limited SNP
panel with regards to potential predictive accuracy, area under the
receiver-operator characteristic curve (AUC)was conducted. Poly-
genic risk scores from unrelated individuals with diagnoses of BPI
or SAB from the NIMH family sample (n¼ 236) were compared
with unrelated controls from the TGEN dataset (n¼ 266). The
AUC was modestly increased from the null at a¼ 0.05 (AUC
¼ 0.60; 95%CI¼ 0.55–0.65). A score of 32 risk alleles had sensi-
tivity of 60% and specificity of 52%, and a score of34 risk alleles
had sensitivity of 40% and specificity of 73%. Results were similar
in analyses weighted by allele frequency (AUC¼ 0.57; 95%CI
¼ 0.52–0.62) and odds ratio (AUC¼ 0.60; 95%CI¼ 0.55–0.65).
Based on the genetic epidemiology of bipolar disorder (i.e., disease
prevalence and sibling recurrence risk), the maximum theoretical
value for AUC is 0.97 or 0.80 if the variants included in the genomic
profile explain a quarter of the known genetic variance [Wray et al.,
2010]. The proportion of the known genetic variance explained by
the 32 SNP genomic profile (rG^G) is approximately 3%, and the
proportion of variance explained by the score on the liability scale
was estimated at Nagelkerke’s R2¼ 0.0088 0.0062.
Iterative inclusion of SNPs ranked by odds ratios revealed that
the AUC estimate increased with the addition of each SNP, with the
AUC statistic becoming significant (i.e., P 0.05) with the inclu-
sion of 14 SNPs with the highest odds ratios (OR 1.15) (Table II).It must be noted however, that while significant, the predictive
capacity of the PRS is low, indicative of the small effect sizes of
individual risk alleles.Polygenic Risk Load Analysis Within Families,
Comparing Adult Relatives With Bipolar Disorder
to Other Relatives
We next sought to examine polygenic risk scores within multiplex
families, to determine if the average polygenic risk score would be
higher in cases compared to other relatives. We used European
ancestry subjects from 249 bipolar pedigrees from the NIMH
genetics initiative, and applied a narrow diagnostic model, where
only subjects with diagnoses of BPI or SAB were considered to be
cases (n¼ 601). The category “all other relatives” (n¼ 695) in-
cluded subjects with other mental illness (i.e., those with any DSM
diagnosis excluding BPI, SAB, BPII, or UPR) and those who were
never mentally ill.
As inheritanceofpolygenic riskhasnotpreviously been examined
in a family context, we first examined the relationship between risk
scores amongst related individuals in each family. We selected all
available sibling pairs from the 249 NIMH families (n¼ 777 pairs),
and examined the sibship correlation in polygenic risk score. As
expected, risk scores amongst all siblings regardless of phenotype
were significantly correlated (Pearson R¼ 0.53, P¼ 3.60 1057),
with an absolute mean score difference (ABS[sib1 sib2]) of3.74
risk alleles (Fig. 2). Less predictably, phenotypically concordant case
pairs (n¼ 108) did not have significantly different absolute mean
score differences compared to phenotypically discordant sibpairs
(n¼ 103) and concordant non-case pairs (n¼ 95) (ANOVA,
F¼ 1.38, P¼ 0.25).
Next, we examined polygenic risk score differences amongst all
relatives in a within-family analysis (n¼ 249 families), comparing
all cases affected with BPI or SAB (n¼ 600) to all other relatives
(n¼ 695).We found no significant differences by diagnostic group
across all families (mean¼ 32.69 3.94 vs. 32.45 3.85; Wald
FIG. 2. Relationship between polygenic risk scores in sibling pairs from NIMH families. A) Distribution of polygenic risk score difference
between sibpairs (n¼ 777). B) A significant correlation between polygenic risk scores of sibling pairs was observed (n¼ 777, Pearson
R¼ 0.53, P¼ 3.60E-57).
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(Fig. 3A).
However, given the heterogeneity of bipolar disorder we hy-
pothesized that some families will have a higher load of these
specific common variants than others, and that polygenic risk scoreFIG. 3. Analysis polygenic score by diagnosis in NIMH families comparing
patients affected with BPI or SAB (dark grey bars) were compared to all
representation, the frequency of risk scores are represented in even inte
(i.e., bin 22 is the sum of the frequency of 22 and 23 risk alleles). Relat
risk score of 32. A) All NIMH families (n¼ 249) included 600 cases an
between mean risk scores in case versus all other relative groups (mean
P¼ 0.13). Relative risk was not significant (RR¼ 1.06 (95%CI¼ 0.96–1.
(n¼ 202), where two or more individuals from each family had a risk sc
(n¼ 518) compared to all other relatives (n¼ 613)(mean¼ 33.40 3.6
of risk scores in patients affected with BPI or SAB were shifted significan
significant increase in relative risk in cases (RR¼ 1.32 (95%CI¼ 1.03–1differences may be informative of diagnosis only in families which
carry a high load of these specific common variants of small effect,
as opposed to families whose illness may be caused largely by
inheritance of rare pathogenic variation in a smaller number of key
genes.cases to all other relatives. The distribution of risk scores in
other relatives (light grey bars). For the purposes of graphical
gers, and represent bins which include both odd and even scores
ive risk (RR) estimates were calculated with respect to an additive
d 715 other relatives. No significant differences were observed
¼ 32.69 3.94 vs. 32.45 3.85; GEE-Wald x2¼ 1.19, df¼ 1,
17), P¼ 0.14). B) Selected NIMH families with a high polygenic load
ore of 32. The mean risk score was significantly higher in cases
2 vs. 32.95 3.70; GEE-Wald x2¼ 4.78, P¼ 0.014). The distribution
tly towards the right compared to their other relatives, with a
.70), P¼ 0.018).
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individuals (regardless of diagnosis) had a high-polygenic risk
score (i.e., 32) and repeated the analysis in those 202 families.
We found that the polygenic risk score significantly differentiated
the diagnostic groups in families with a high-common variant
load, such that cases (n¼ 518) had higher polygenic risk scores
than other relatives (excluding those with diagnoses of BPII or
UPR; n¼ 613) (Wald x2¼ 4.78, P¼ 0.014; RR¼ 1.32 [95%CI
¼ 1.03–1.70], P¼ 0.018) (Fig. 3B). This was also significant when
subjects affected with BPII were included as cases in the model
(n¼ 621 cases vs. 613 other relatives; mean¼ 33.31 3.61 vs.
32.92 3.70; Wald x2¼ 3.53, P¼ 0.030; RR¼ 1.26 [95%CI
¼ 1.00–1.60], P¼ 0.032).Polygenic Risk Load Analysis in Young First
Degree Relatives At-Risk of Bipolar Disorder
Next, we examined polygenic risk in young at-risk subjects of
European ancestry (n¼ 334) and compared those to age- and
ethnically appropriate controls (n¼ 142). The at-risk group showed
higher mean scores than controls (GEE-Wald x2¼ 5.15, P¼ 0.012)
(Fig. 4A). The relative risk estimate for subjects with scores32 was
1.20 ([95%CI¼ 0.99–1.45], P¼ 0.036) (Fig. 4B). Results were simi-
lar in analyses weighted by allele frequency (GEE-Wald x2¼ 5.55,
P¼ 0.009) and odds ratio (GEE-Wald x2¼ 4.18, P¼ 0.020).
Expanding the cohort to include subjects from the three main
ethnic groups (i.e., European, Asian, and African) in an ethnicity-
specific weighted analysis showed an enrichment of risk alleles in
at-risk subjects compared to controls (GEE-Wald x2¼ 3.62,FIG. 4. Polygenic risk score analysis in young European at-risk individua
individual were scored using an additive model, using only subjects of Eu
represented by the grey and white bars, respectively. A) The mean risk s
controls (31.07 0.31) (GEE-Wald x2¼ 5.15, 0.012). B) The distribution
relative to control subjects. For the purposes of graphical representation
represent bins which include both odd and even scores (i.e., bin 22 is th
(RR) estimate of 1.20 (95%CI¼ 0.99–1.45) was calculated with respect
CI¼ 0.99–2.09).P¼ 0.029; RR¼ 1.14 [95%CI¼ 1.01–1.29], P¼ 0.017) (Supple-
mentary Information Figure S1).DISCUSSION
Many genomic variants together contribute to overall risk (termed
polygenic risk) for a number of complex traits [Peterson et al.,
2011; Hamshere et al., 2013; Meyers et al., 2013], and this genetic
architecture is evident in a number of psychiatric conditions—
including BP [Purcell et al., 2009; Lee et al., 2012, 2013; Smoller
et al., 2013; Bramon et al., 2014]. While the elucidation of the
genetic causes for BP has been challenging, the field is progressing
in understanding the genetic architecture of this complex disorder
(reviewed in [Craddock and Sklar, 2013]) and in identifying
specific genes which increase risk [Sklar et al., 2011]. Polygenic
risk scores based on multiple genetic variants across the genome
[Purcell et al., 2009] have successfully discriminated between
groups of unrelated cases and controls [Patel et al., 2010] and
also individuals with BP broadly defined as schizoaffective or non-
schizoaffective [Hamshere et al., 2011], indicating the potential
utility of risk score analysis in clinical diagnoses at a population
level. However, it is unclear as to whether polygenic risk score
analysis, with or without other clinical or biomarker data, could be
useful for diagnosis or risk prediction in persons with a significant
family history of BP, particularly given the non-random inheri-
tance of population risk alleles in related individuals and con-
founding shared environmental effects within a family. This
question is also pertinent due to the potential for high rates of
sporadic illness in typical gene discovery studies [Yang et al.,
2010]which are used to define commonpolygenic risk. The presentls compared to controls. The total numbers of risk alleles per
ropean descent. At-risk (n¼ 334) and control (n¼ 142) groups are
core was significantly higher in at-risk subjects (31.99 0.27) than
of risk scores in at-risk subjects was shifted toward the right
, the frequency of risk scores are represented in even integers, and
e sum of the frequency of 22 and 23 risk alleles). The relative risk
to a risk score of 32, with an overall odds ratio of 1.44 (95%
624 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bstudy is the first to examine these common risk factors in the
context of inheritance within the family of a BP proband, exploring
both adult relatives of known diagnosis, and adolescent or young
adult relatives who are at-risk of future BP on the basis of a positive
family history.
Determination of polygenic risk scores can be performed using
strict (e.g., genome-wide significant P< 5 108) or increasingly
permissive P-value thresholds to include variation with very small
genetic effects which may impact disease status. We chose to focus
our study on 32 SNPs that were the most significant independently
associated variants in the PGC-GWAS analysis [Sklar et al., 2011].
While we acknowledge that our limited SNP selection represents
only a small fraction of the total variation that contributes to bipolar
disorder risk [Lee et al., 2011, 2013], the selected SNPs arguably
represent the largest effect sizes on a population level and are
potentially least subject to statistical fluctuation and type I error.
We first sought to determine whether this SNP panel could be
useful in distinguishing individuals with a diagnosis of narrowly
defined bipolar disorder from unrelated control individuals. The
AUC value of the SNP panel (0.60) was small but significant, and
slightly higher than the median AUC values based on “known”
bipolar risk variants (n¼ 3) with genome-wide SNP data at a more
liberal P-value inclusion threshold of P< 0.0001–0.01 that was
previously reported in the WTCCC dataset [Evans et al., 2009].
This may indicate that the larger PGC analysis has a greater signal-
to-noise ratio in the top risk SNPs than those identified in the
earlier WTCCC analysis, and is consistent with simulation studies
which indicate that the accuracy of diagnostic prediction using
polygenic risk scores depends on the size of the training sample
[Purcell et al., 2009; Dudbridge, 2013].
We found that polygenic risk scores significantly distinguished
between diagnostic groups in families with a higher polygenic risk
load, but not in families with moderate–low polygenic loads—con-
sistent with genetic heterogeneity across families. Risk scores were not
sufficiently specific to classify diagnostic status on an individual basis.
Remarkably, we were also able to identify group differences between
young individuals at-risk of BP and young controls.
The PGC discovery sample from which the selected SNPs were
derived was ethnically European, and as such we restricted our
primary analysis to subjects of European descent. By expanding the
analysis to include the three major ethnic groups represented in the
at-risk cohort, we assume the same SNPs and alleles will confer risk
across different ethnic groups. There is little clear evidence regarding
ethnic-specific locus-heterogeneity, partly due to the smaller sample
sizes currently available for non-European gene discovery studies.
However, a recentmeta-analysis of European andAsianGWASdata
has shown that Asian subjects tend to have the same direction of
effect for themost significantly associated loci (P< 1e-06) with only
2%of the top 41 SNPs showing a different direction of effect to the
European samples [Chen et al., 2013]. Additional method develop-
ment to address the use of polygene scores in the presence of ethnic
differences would be useful.
The purpose of our study was to determine whether a small
number of common risk variants could be useful in distinguishing
relatives of BP probands who are also ill, or may become ill in the
future. Despite the close genetic relationship between extended
family members, and a non-random inheritance of risk alleleswithin a family, we were able to show that the polygenic risk score
did serve as amarker of ill versus well relatives on a group basis. We
would not recommend clinical application of such a score at this
time, but additional implementation of similar methods in longi-
tudinal clinical research studies is certainly called for.
Only one other group thus far has examined polygenic risk in a
prospectively recruited bipolar cohort, showing an increased ge-
nome-wide polygenic risk score in 70 at-risk individuals compared
to 60 controls [Whalley et al., 2013] at baseline assessment. This
group has also reported polygene associations with limbic brain
activation during functional MRI [Whalley et al., 2012], and white
matter integrity measures from DTI in a bipolar at-risk cohort
[Whalley et al., 2012]. Neuroimaging biomarkers have previously
been identified in the Australian at-risk subjects which were part of
the current study, with a lack of recruitment of the inferior frontal
gyrus in the high-risk participants compared to healthy controls
during an fMRI emotion inhibition task [Roberts et al., 2013].
Further investigations on the impact of polygenic risk on neuro-
imaging biomarkers may be particularly informative.
While this paper describes baseline associations of this at-risk
cohort, future investigation of this sample—which is being pro-
spectively evaluated as subjects transition through the peak period
of risk for the development of BP—will be able to determine if
polygenic risk scores are useful in future risk prediction for the
development of bipolar disorder. It remains to be seen as to
whether polygenic risk scores alone [Patel et al., 2010], or in
conjunction with early clinical signs, exposure to psychosocial
risk factors, and other potential biomarkers [Brietzke et al.,
2012] may provide a more robust predictor of future illness.
The predictive power of polygenic risk scores is likely to improve
with increased discovery sample sizes and the assessment of a larger
number of both common and rare genetic variants within the
prediction models [Sullivan et al., 2012; Chatterjee et al., 2013;
Craddock and Sklar, 2013; Dudbridge, 2013].LIMITATIONS
Some of the parents or relatives of the US at-risk subjects were
ascertained from the NIMH families which were included in the
PGC discovery sample, and hence our family samples are not
entirely independent. However, there is no overlap between the
Australian at-risk subjects and the PGC discovery sample, nor are
the Australian at-risk subjects related to this sample. While the
overall contribution of those NIMH relatives to the PGC discovery
sample was very small (<2% of the cases from the PGC discovery
dataset), our findings should be considered as an extension rather
than an independent replication of the PGC findings (see also
discussion in [Wray et al., 2013]). Using only the most significant
SNPs is also a limitation of our study, and we acknowledge that
many more variants of importance in conferring risk to bipolar
disorder have not been assessed. Conversely, this is also a strength
of our study, as wewere able to directly genotype each variant in the
at-risk and family samples, rather than relying on imputed data or
surrogate SNPs. Indeed, fewer than half of the 32 SNPs in our panel
are represented on any one high-density SNP chip currently
commercially available, although direct genotyping of a larger
number of SNPs showing nominally significant association will
FULLERTON ET AL. 625be possible with the PsychChip (Illumina, San Diego, CA). Impu-
tation was used in the determination of genotypes in the unrelated
control group for AUC estimation, and while imputation accuracy
was high (97.4% concordance), this is a limitation of the AUC
analysis and, together with the small overlap between the PGC
discovery sample and the US family samples, should be taken into
consideration with interpretation of the AUC data [Wray et al.,
2013]. It should be noted that limitations of genotyping platform
and imputation did not apply to the key within-family results. We
also applied a genetic model which assumes additivity of risk alleles
in a single aggregate score as per the methods used by the PGC
[Purcell et al., 2009], although it should be noted that this is a
simplistic model which does not account for possible multiplica-
tive interaction effects between genes or genes and environment.CONCLUSIONS
Our study provides conceptual support to the notion that poly-
genic risk scores may be useful in prospective risk prediction for
bipolar disorder. This may lead to future opportunities for early
identification and intervention strategies, such as prophylactic
pharmaceutical treatment, environmental modifications, or tar-
geted psychological interventions (reviewed in [McMurrich et al.,
2012; McNamara et al., 2012]) to reduce the impact and develop-
ment of symptoms, improve quality of life, and long-term out-
comes for patients.ACKNOWLEDGMENTS
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